Press releases

System had earlier received FDA clearance and CE Mark approval for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures.

Bipartisan bill is intended to modernize the U.S. patent system

Low-profile, high-pressure balloon offers physicians exceptional performance in a single platform for peripheral angioplasty procedures

Company will participate in the healthcare conference on June 22 in Boston. Learn how to watch the webcast or replay.

Patents relate to coatings (drug and polymer) for drug-eluting stents

Action affects products distributed in U.S. and its territories; Atlantis® SR Pro available immediately as a substitute

Boston Scientific becomes the first and only company to offer two distinct drug-eluting stents to treat small vessels

New technology designed to improve lead anchoring for physicians to be introduced at INS World Congress

12-month clinical data demonstrate low adverse event rates for Boston Scientific's 2.25 mm PROMUS Element Platinum Chromium Stent

Results for Boston Scientific WATCHMAN device presented at EuroPCR

Five-year data from RISA Trial presented at ATS adds to clinical evidence showing long-term safety of Boston Scientific's Alair® Bronchial Thermoplasty System

Jury in the District of Delaware found that Cordis owed Boston Scientific approximately $19.5 million for infringing its Jang patent.

Patients receive first device-based treatment for severe asthma

Elliott to remain on Board as non-executive director.

Company sponsors additional efforts to promote education and awareness of severe asthma

Innovative Fine Needle Aspiration technology expands diagnostic capabilities in pancreas and gastrointestinal tract

World's smallest and thinnest high-energy CRT-Ds and ICDs offer new features to optimize patient management

ALTITUDE analyzes outcomes data from patients monitored by the LATITUDE® Patient Management system.

Implanting U.S. centers can qualify for a full refund if they have to replace a COGNIS® CRT-D device due to unmanageable PNS within six months post-implant.

System used in 25,000 patient procedures at 600 facilities worldwide since 2007

Radiofrequency ablation catheter designed to treat a variety of arrhythmias

The scheduled clinical presentations will provide new insights for physicians who treat patients with heart disorders including sudden cardiac arrest, atrial fibrillation and heart failure.

Company will participate in the healthcare conference on May 11 in Las Vegas. Learn how to watch the webcast or replay.

Company will participate in the healthcare conference on May 2 in Boston. Learn how to watch the webcast or replay.

Innovative alloy designed to improve new coronary stent's acute performance

“We had several notable accomplishments during the quarter that illustrate progress toward strategic milestones,” said Ray Elliott, Company President and CEO.

Company will webcast its conference call with financial results and business highlights for Q1 2011 on April 21. Learn how to tune in.

Study will evaluate safety and effectiveness in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).

Reduction of geographic miss and bail-out stenting observed with highly visible PROMUS Element Stent

Lower event rates for new alloy and stent design versus older drug-eluting stent model

Clinical presentations to include 12-month data on PROMUS Element™ Platinum Chromium Stent

New technology designed to improve lead anchoring speed and consistency for physicians

Company will provide an update on its Cardiology, Rhythm and Vascular (CRV) Group initiatives involving coronary stent and structural heart technologies

Company will participate in the healthcare conference on March 15. Learn how to watch the webcast or the replay.

Third-generation bare-metal stent offers improved acute performance in treating patients with coronary artery disease

Company adds innovative technology for atrial fibrillation patients with high stroke risk

Company's third-generation drug-eluting stents now available in rapidly growing market

Company will participate in the healthcare conference on March 2. Learn how to tune in.

New products expand treatment options for healthcare providers

Scholarship Fund Honors Company's Late Chief Medical and Scientific Officer

Journal of American College of Cardiology sub-analysis showed women received a greater clinical benefit from cardiac resynchronization therapy defibrillators (CRT-Ds) than men

New system integrates market-leading Renegade HI-FLO Microcatheter with high-torque Fathom-16 Steerable Guidewire for peripheral embolization procedures

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2010, as well as net...

Complaint involves Guidant's conduct leading to its recalls of ICDs in 2005, before Boston Scientific’s 2006 acquisition of Guidant

Procedure performed as part of BLOCk-CTI clinical trial evaluating treatment of Type 1 atrial flutter

PLATINUM China trial to support Chinese regulatory approval of next-generation platinum chromium stent

Fourth-generation stent features bioabsorbable polymer and everolimus drug coating

Distribution agreement will allow Company to expand the service it offers customers in Japan

A live webcast and archived replay of this call will be available

Innovative left atrial appendage closure device offers alternative for patients with atrial fibrillation and strengthens Company's position in emerging structural heart markets

ORION clinical trial designed to evaluate EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease

Boston Scientific Corporation (NYSE: BSX) today announced it has acquired Intelect Medical, Inc., a development-stage company located in...

Article reported on a study that found about 20 percent of patients who received an implantable cardioverter defibrillator (ICD) did not meet evidence-based guidelines

Acquisition brings Boston Scientific the first fully repositionable device for percutaneous aortic valve replacement to treat severe aortic stenosis

Company prepays $600 million of debt

Company will participate in the conference on January 11, 2011. A live webcast and replay will be available.

Distinguished leader brings broad range of expertise in science, technology, business, education and government

Patients experienced a 50 percent relative reduction in risk of death compared to in-clinic follow-up

Company will participate in the conference on December 1, 2010. A live webcast and replay will be available.

Innovative percutaneous aortic valve replacement system provides entry into emerging market of structural heart disease

INCEPTA™, ENERGEN™ and PUNCTUA™ designed to advance patient care with options to expand appropriate therapy, optimize ventricular pacing and manage heart failure

Awards recognize breakthrough products and technologies that represent a significant leap forward in their respective categories

Company supports efforts of International Diabetes Federation to promote worldwide diabetes education and prevention

Company's November 19, 2010 meeting will be simultaneously webcast; learn how to tune in live or access the replay.

Company implants its first Deep Brain Stimulation device designed to treat Parkinson's

Boston Scientific Corporation (NYSE: BSX) today announced that its newly acquired subsidiary, Asthmatx, Inc., presented two-year...

Proceeds to allow Company to invest in future growth opportunities while also reducing overall debt leverage

Acquisition brings the Alair® Bronchial Thermoplasty System, the first device-based asthma treatment approved by the FDA

Company's fully covered metal stent now approved for use in treating benign biliary strictures

Latest innovation in plastic biliary stent technology includes features for enhanced deliverability, efficiency and procedural control

CEO Ray Elliott notes financial results reflect “strong operating performance despite the challenges facing our industry.”

Major advance in guidewire technology for challenging peripheral interventions

Company will webcast its conference call on Tuesday, October 19. Learn how to tune in or watch the replay.

MADIT II eight-year outcomes analysis shows that one life is saved for every eight patients who receive an ICD

Largest randomized trial to compare the use of drug-eluting stents to bare-metal stents for AMI patients

Company presents one-year clinical data at TCT on its platinum chromium paclitaxel-eluting coronary stent from PERSEUS trial

Results of TAXUS ATLAS clinical program presented at TCT

Nine-month results from PLATINUM clinical program presented at TCT

Indications are important additions, especially as diabetes prevalence continues to increase worldwide

Offers first FDA-approved non-drug procedure for the treatment of severe asthma

FDA approval is based on results from the Company's landmark MADIT-CRT trial

Company to present clinical data on its platinum chromium PROMUS® Element™ and TAXUS® Element™ Coronary Stent Systems

Company to participate in the September 14th conference in New York City; live webcast and replay will be available

Presentations to feature Boston Scientific's pelvic floor reconstruction systems and mid-urethral sling systems

Resolution "marks a major milestone in our journey of continuous quality improvement," said Ray Elliott, President and Chief Executive Officer

EVOLVE trial to evaluate Company's fourth-generation SYNERGY™ drug-eluting coronary stent

Company now offers pain specialists the most comprehensive portfolio of SCS percutaneous leads

Company to participate in the August 5th conference in New York; live webcast and replay will be available

Company expands market-leading family of neurovascular stents

"I am proud of the way the organization executed in a number of key areas during the quarter," said Ray Elliott, President and CEO

Trial data to help develop a clinical alert that identifies the early onset of worsening heart failure

Company to webcast its conference call with Q2 2010 financial results and business highlights on July 21

Two new splitters allow multi-site placement of up to four spinal cord stimulation leads

Refinancing to help strengthen Company’s capital structure and provide enhanced capacity to fund acquisitions and other investments in technologies

Longer balloons provide physicians more options for treating peripheral artery disease

Women experienced a 70 percent reduction in heart failure events compared to a 35 percent reduction for men

Company to participate in the healthcare conference on June 24 in Boston; live webcast and replay will be available

Presentations to include results of the MADIT-CRT trial and the ALTITUDE clinical science program

CE Mark approval includes specific indication for treatment of diabetic patients

Company to participate in the June 16th conference in Los Angeles; live webcast and replay will be available